Drug Trial Radar · NCT02089087
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Dose CFZ533 in Rheumatoid Arthritis Patients
Last checked: Nov 19, 2026Latest source record: Dec 11, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
75
Actual
Start
Jan 7, 2013
Primary completion
Feb 3, 2017
Study completion Feb 3, 2017
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Mar 17, 2014
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a first-in-human study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single intravenous and subcutaneous doses of CFZ533 in healthy subjects and intravenous doses in rheumatoid arthritis patients.
Conditions
- Rheumatoid Arthritis
Interventions
CFZ533Biological
Single dose at varying dosage levels depending on treatment assignment
PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of patients with adverse events as a measure of safety and tolerabilityTime frame: 7 months
Locations
6 sites in 2 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Anniston, Alabama
Novartis Investigative Site
Miami, Florida
Novartis Investigative Site
South Miami, Florida
Novartis Investigative Site
Lincoln, Nebraska
Novartis Investigative Site
Duncansville, Pennsylvania
Novartis Investigative Site
Taipei, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.